Steven Valiquette
Stock Analyst at Mizuho
(2.59)
# 1,146
Out of 4,829 analysts
107
Total ratings
55%
Success rate
11.88%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALGN Align Technology | Maintains: Outperform | $250 → $245 | $189.00 | +29.63% | 11 | Apr 29, 2025 | |
| MCK McKesson | Maintains: Neutral | $630 → $690 | $687.52 | +0.36% | 3 | Apr 3, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $142 → $150 | $148.62 | +0.93% | 6 | Mar 31, 2025 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $21 → $18 | $16.75 | +7.46% | 7 | Mar 13, 2025 | |
| SOLV Solventum | Maintains: Neutral | $70 → $82 | $74.80 | +9.63% | 2 | Mar 3, 2025 | |
| DOCS Doximity | Maintains: Neutral | $55 → $65 | $61.04 | +6.49% | 2 | Feb 10, 2025 | |
| VEEV Veeva Systems | Maintains: Outperform | $275 → $280 | $241.44 | +15.97% | 2 | Dec 9, 2024 | |
| LFMD LifeMD | Initiates: Neutral | $7 | $8.55 | -18.13% | 1 | Dec 4, 2024 | |
| HQY HealthEquity | Initiates: Outperform | $126 | $96.66 | +30.35% | 1 | Dec 4, 2024 | |
| HSIC Henry Schein | Initiates: Neutral | $75 | $70.47 | +6.43% | 5 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.08 | +62.34% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $20 | $18.55 | +7.82% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $14 | $7.15 | +95.80% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $191.55 | -25.87% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $65.13 | -15.55% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $145.63 | -36.83% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $378.75 | +49.17% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $64.81 | +54.30% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $5.20 | +169.23% | 1 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $327.69 | +22.07% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $62.87 | +70.19% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $28.66 | -40.68% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $6.84 | +75.44% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $116.93 | -17.90% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $175.90 | -31.78% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $363.28 | -65.04% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $252.86 | +41.58% | 3 | Dec 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $78 → $60 | $11.40 | +426.32% | 3 | Apr 3, 2019 |
Align Technology
Apr 29, 2025
Maintains: Outperform
Price Target: $250 → $245
Current: $189.00
Upside: +29.63%
McKesson
Apr 3, 2025
Maintains: Neutral
Price Target: $630 → $690
Current: $687.52
Upside: +0.36%
Cardinal Health
Mar 31, 2025
Maintains: Outperform
Price Target: $142 → $150
Current: $148.62
Upside: +0.93%
DENTSPLY SIRONA
Mar 13, 2025
Maintains: Neutral
Price Target: $21 → $18
Current: $16.75
Upside: +7.46%
Solventum
Mar 3, 2025
Maintains: Neutral
Price Target: $70 → $82
Current: $74.80
Upside: +9.63%
Doximity
Feb 10, 2025
Maintains: Neutral
Price Target: $55 → $65
Current: $61.04
Upside: +6.49%
Veeva Systems
Dec 9, 2024
Maintains: Outperform
Price Target: $275 → $280
Current: $241.44
Upside: +15.97%
LifeMD
Dec 4, 2024
Initiates: Neutral
Price Target: $7
Current: $8.55
Upside: -18.13%
HealthEquity
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $96.66
Upside: +30.35%
Henry Schein
Dec 4, 2024
Initiates: Neutral
Price Target: $75
Current: $70.47
Upside: +6.43%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $3.08
Upside: +62.34%
Dec 4, 2024
Initiates: Underperform
Price Target: $20
Current: $18.55
Upside: +7.82%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $18 → $14
Current: $7.15
Upside: +95.80%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $191.55
Upside: -25.87%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $65.13
Upside: -15.55%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $145.63
Upside: -36.83%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $378.75
Upside: +49.17%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $64.81
Upside: +54.30%
Feb 27, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $5.20
Upside: +169.23%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $327.69
Upside: +22.07%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $62.87
Upside: +70.19%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $28.66
Upside: -40.68%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $6.84
Upside: +75.44%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $116.93
Upside: -17.90%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $175.90
Upside: -31.78%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $363.28
Upside: -65.04%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $252.86
Upside: +41.58%
Apr 3, 2019
Maintains: Equal-Weight
Price Target: $78 → $60
Current: $11.40
Upside: +426.32%